Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib with Etoposide in Relapsed Metastatic Germ-cell Tumor
NCT06937866Phase 2Recruiting
- Sponsor
- Indiana University
- Start
- Nov 2025
- Primary completion
- Mar 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of zanzalintinib in germ cell tumor (GCT) (2 arms), sponsored by Indiana University. Primary endpoints: Rate of hematologic toxicity at 28 days, Rate of non-hematologic toxicity at 28 days and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT06937866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937866.